NCATS Director Christopher Austin, M.D., and Taylor Gilliland, Ph.D., an NCATS health scientist, recently joined other translational science experts in Vancouver, Canada, to discuss global efforts in education and training, reproducibility and attrition, cross-sector collaboration, and data sharing. Other organizations represented included the Canadian Centre for Drug Research and Development, European Infrastructure for Translational Medicine, the Czech Institute of Molecular and Translational Medicine, and Therapeutic Innovation Australia.
-
Research
-
- Funding & Notices
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Stem Cell Translation Laboratory
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- A Translational Approach to Addressing COVID-19
- Antiviral Program for Pandemics
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes
- Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey
- National COVID Cohort Collaborative (N3C)
- The Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (BGTC)
- NIH Common Fund Programs
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Functional Genomics Lab
- Therapeutics for Rare and Neglected Diseases (TRND)
- About NCATS
- Home
- News & Media
- Stories & Publications
- NCATS E-Newsletter
- Past E-Newsletter Issues
- Translational Science Representatives Meet to Advance Field
Translational Science Representatives Meet to Advance Field
- Funding & Notices
-